Verify any claim · lenz.io
Claim analyzed
Health“Among patients 12 months after ST-elevation myocardial infarction, those with high-sensitivity C-reactive protein levels greater than 26.4 mg/L had a 12% rate of major adverse cardiovascular events, compared with a 4% rate among those with high-sensitivity C-reactive protein levels at or below 26.4 mg/L.”
Submitted by Daring Owl df4c
The conclusion
Open in workbench →The quoted 12% versus 4% event rates are supported by a 2024 peer-reviewed STEMI study. However, those numbers came from a selected cohort followed for about 12 months, and the 26.4 mg/L threshold was the study's median hs-CRP level, not a broadly accepted universal cutoff. The data are accurate, but the wording is slightly broader than the underlying evidence.
Caveats
- The 26.4 mg/L threshold was a study-specific median value, not a standard clinical hs-CRP cutoff used across cardiology.
- The reported rates came from a particular STEMI cohort with cardiac MRI follow-up, so they should not automatically be generalized to all STEMI patients.
- The phrasing can be read as a fixed 12-month landmark result, while the study reported cumulative events over roughly 12 months of follow-up.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
This study found that patients with higher hs-CRP were at greater risk of major adverse cardiovascular events. The abstract states that patients with hs-CRP ≥2 mg/L had a higher risk of major adverse cardiovascular events (n=3900; adjusted hazard ratio 1.28, 95% CI 1.18-1.38) and that results remained robust after exclusion of events occurring during the first 6 to 12 months.
This review summarizes data that "hs-CRP can be associated with major adverse cardiovascular events (MACE) in patients with a large anterior STEMI undergoing primary percutaneous coronary intervention (PCI)." It notes that "preprocedural hs-CRP is independently associated with MACE and all-cause death in patients with primary PCI during a median follow-up period of 6.5 years" and that in AMI patients after PCI, "baseline hs-CRP was an independent predictor for MACE at 36‑month follow-up." However, the review does not specify a 26.4 mg/L cutoff or 12‑month MACE rates of 12% vs 4%.
Furthermore, patients with hs-CRP levels above the median (>26.4 mg/L) were more likely to experience major adverse cardiac events (12% vs 4%, P = 0.002) during a median follow-up of 12 (Q1-Q3: 12-13) months. In the present CMR study, we observed a significant association between circulating inflammatory biomarkers and I/R injury, defined by the presence of IMH as assessed by CMR T2* mapping. In particular, hs-CRP levels at 48 hours after PCI emerged as independent inflammatory biomarker associated with IMH.
In this study of patients with ST-elevation myocardial infarction treated with primary angioplasty and stent implantation, the authors state: "No statistically significant association was observed between high-sensitivity C-reactive protein and recurrent MACE (p = 0.11)." They conclude that "hs‑CRP was not predictive of composite MACE within the first 30 days after acute ST-elevation myocardial infarction" but was an independent predictor of 30‑day mortality. The paper does not report a 26.4 mg/L threshold or 12‑month MACE rates of 12% versus 4%.
The incidence of total MACE, defined as the composite of all-cause death, non-fatal MI, ischemic stroke, hospitalization for unstable angina leading to revascularization, and HFH, was assessed in long-term follow-up post-index hospitalization for acute STEMI. In addition, patients with CRP1M ≥ 2 mg/L at one month after index hospitalization for STEMI exhibited higher risk of HF hospitalization long-term. Measurement of CRP during hospitalization for STEMI and at one month after discharge can aid in identifying patients who are most likely to benefit from early implementation of anti-inflammatory strategies for preventing HF in long-term follow-up.
The article states that hsCRP ≥2 mg/L is associated with increased risk of MI, stroke and other cardiovascular events, and that in established ASCVD elevated hsCRP is a marker of residual inflammatory risk. It also says hsCRP predicts major adverse cardiovascular events over long follow-up in secondary prevention populations.
There was a significant difference in hsCRP values between patients who had MACE and those without it (38.35 [98.10] vs. 12.97 [23.80], p=0.0001). Our study showed that there was a significant difference in hsCRP values between patients who had MACE (fatal outcome, reinfarction, heart failure, and re-revascularization), within six months from the pPCI, and those who did not have MACE: 38.35 (14.38–112.50) and 12.97 (6.00–29.80), p<0.001. At the cut-off point of 24.15 mg/L (calculated using the Youden’s index), the hsCRP may predict MACE with a sensitivity of 0.647 and specificity of 0.693.
This study examines associations between initial systolic blood pressure, biomarkers of systemic inflammation (including hs-CRP), and outcomes in acute coronary syndrome (ACS).[5] It defines MACE as a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.[5] At 30 days, the authors report MACE occurred most frequently in those with systolic blood pressure <100 mmHg (8.8 vs. 3.8 vs. 3.6%, adjusted P < 0.001).[5] Although hs-CRP is one of the inflammatory markers, the paper focuses on blood pressure strata and does not report a hs-CRP threshold of 26.4 mg/L, nor 12‑month post‑STEMI MACE rates of 12% vs. 4%.
This earlier study evaluated hs-CRP and prognosis in acute STEMI. According to the abstract, "Patients were divided into quartiles according to hs-CRP levels." It reports that patients in the highest hs-CRP quartile had significantly higher mortality and heart failure at follow-up compared with those in lower quartiles. The study uses quartile-based stratification rather than a defined cut-off of 26.4 mg/L and does not present 12‑month MACE rates of exactly 12% vs. 4%.
This prospective study evaluated admission CRP as a predictor of 30-day major adverse cardiovascular events in acute myocardial infarction patients. It found that elevated CRP levels were significantly associated with higher MACE incidence, with the highest risk in the >10 mg/L group.
This study, related to the PMCID article above, assessed hs-CRP in STEMI treated with primary angioplasty and stenting. The abstract notes: "Hs-CRP was not predictive of combined major adverse cardiovascular events (MACE) within 30 days after ST-elevation myocardial infarction, but was an independent predictor of 30-day mortality." The reported outcomes are limited to 30 days; no 12‑month MACE rates of 12% and 4% at a threshold of 26.4 mg/L are described.
This study investigates outcomes in STEMI patients undergoing primary PCI according to hs-CRP levels. The abstract explains that hs-CRP was measured and patients were categorized according to baseline hs-CRP, with higher levels associated with worse clinical outcomes including mortality and heart failure at follow-up. While it shows a graded relationship between hs-CRP and outcomes, the abstract and available text do not identify a specific cut point at 26.4 mg/L or report 12‑month MACE rates of 12% versus 4% at that threshold.
This paper evaluates multiple inflammatory markers, including high-sensitivity C-reactive protein, and their association with 1‑year outcomes in STEMI patients treated with primary percutaneous coronary intervention. The abstract indicates that elevated inflammatory markers were associated with higher rates of death and heart failure at one year. However, the study’s reported analyses do not use a fixed hs-CRP threshold of 26.4 mg/L, nor do they specify a 12% versus 4% 1‑year MACE rate for patients above or below that value.
The present study shows a lower intensity of inflammatory response, as assessed by plasma CRP concentration measured during the acute phase of a first STEMI treated with pPCI, in patients with preserved global LVSF at six months after hospital discharge, compared to patients with LVEF ≤ 50% at six month follow-up. CRP concentrations 24 h after admission, at discharge and at one month after STEMI were lower in patients with preserved global LVSF at six month follow-up.
The review says elevated hsCRP is associated with major adverse cardiovascular events, and summarizes trial evidence showing increased future cardiovascular risk with higher hsCRP. It also notes the 2019 ACC/AHA recommendation that hsCRP ≥2 mg/L can be used as a risk-enhancing factor.
Residual inflammatory risk was defined as high-sensitivity C-reactive protein ≥ 2 mg/L on statin treatment (or equivalent inflammatory markers). Overall, 5,833 (42.9%) patients were at high residual inflammatory risk 30 days after PCI. At 12-months follow-up, persistent high residual inflammatory risk was associated with an increased risk of MACE compared with those with low inflammatory risk (relative risk 1.64, 95% confidence interval [CI] 1.33–2.03), which was largely driven by a high risk of all-cause death (3.25, 95% CI 2.49–4.25).
High-sensitivity C-reactive protein (hs-CRP) has been associated with adverse outcomes following acute coronary syndromes. In this prospective observational study of patients with STEMI treated with primary PCI, higher hs-CRP levels measured early after admission were significantly associated with increased risk of major adverse cardiovascular events during follow-up. Patients in the highest hs-CRP tertile had the greatest incidence of MACE compared with those in the lowest tertile.
High-sensitivity C-reactive protein (hs-CRP) levels were measured in patients presenting with ST-elevation myocardial infarction treated by primary PCI. During follow-up, patients with higher hs-CRP levels experienced a significantly greater incidence of major adverse cardiovascular events compared with those with lower hs-CRP levels. Multivariate analysis confirmed hs-CRP as an independent predictor of MACE in this population.
The PDF of the same 2020 review on hs‑CRP in STEMI reiterates that hs‑CRP peaks 48–72 hours after STEMI and that higher levels are associated with worse outcomes, including MACE and mortality over follow-up periods up to several years. It summarizes multiple cohort studies but does not show any study defining a cutoff at 26.4 mg/L or reporting that patients above that value had a 12% MACE rate versus 4% for those at or below 26.4 mg/L at 12 months.
In STEMI patients undergoing primary PCI, high-sensitivity C-reactive protein measured within 24 hours after admission was significantly associated with clinical outcomes. Patients with hs-CRP above the optimal cut-off value identified by ROC analysis had a higher rate of major adverse cardiovascular events compared with those below the cut-off during one-year follow-up.
The study evaluated the prognostic value of high-sensitivity C-reactive protein in patients with STEMI. Elevated hs-CRP levels at admission were associated with an increased risk of death and major adverse cardiovascular events during follow-up, independent of traditional risk factors and infarct size.
In cardiology, hs-CRP is commonly reported in mg/L, and residual inflammatory risk after myocardial infarction is often discussed using cut points around 2 mg/L, 3 mg/L, or higher. I do not have a verified source in the provided results for the specific 26.4 mg/L threshold or the exact 12% versus 4% 12-month MACE comparison.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
For developers
This same pipeline is available via API.
Verify your AI's output programmatically.
/extract pulls claims from text ·
/verify returns sourced verdicts ·
/ask answers follow-up questions.
Continue your research
Verify a related claim next.
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
The claim is directly validated by Source 3 (PubMed Central (JACC: Cardiovascular Imaging)), which explicitly states that patients with high-sensitivity C-reactive protein levels above the median threshold of 26.4 mg/L experienced a 12% rate of major adverse cardiac events compared to a 4% rate among those at or below that level. This highly precise finding was recorded during a median follow-up of 12 months in patients who underwent cardiac magnetic resonance imaging after ST-segment elevation myocardial infarction.
The Proponent equivocates between “during a median follow-up of 12 months” and the motion's materially different population framing “among patients 12 months after STEMI,” which implies a 12‑month landmark/post–12‑month cohort rather than cumulative events accrued from the index PCI—exactly what Source 3 reports. The Proponent also treats Source 3's median-split (>26.4 mg/L) in a selected CMR study as if it were a generalizable post‑STEMI threshold, despite the brief showing that the broader literature uses different cut points (often ≥2 mg/L or ROC-derived) and does not replicate the specific 12% vs 4% at 26.4 mg/L (Sources 1, 2, 13, 19, 20).
Argument against
The motion is false as stated because its “12 months after STEMI” framing implies a post-12-month landmark cohort, whereas the only provided evidence matching the 26.4 mg/L split and 12% vs 4% event rates reports outcomes over a median 12-month follow-up from the index event/PCI (Source 3, JACC: Cardiovascular Imaging), not specifically “among patients 12 months after” STEMI. Moreover, the broader STEMI hs-CRP literature in the brief uses very different thresholds (commonly ≥2 mg/L or ROC-derived cutoffs) and does not corroborate a standardized 26.4 mg/L cutoff with those exact 1-year MACE rates (Sources 1, 2, 19, 13, 20), making the motion's precise claim unsupported and misleading.
The Opponent's argument relies on a pedantic misinterpretation of the motion's phrasing, attempting to fabricate a distinction between
Expert review
3 specialized AI experts evaluated the evidence and arguments.
Expert 1 — The Logic Examiner
Source 3 (JACC: Cardiovascular Imaging) directly and explicitly states that patients with hs-CRP above the median (>26.4 mg/L) experienced MACE at 12% vs 4% during a median follow-up of 12 months post-STEMI, which is the precise numerical claim being evaluated; the logical chain from evidence to claim is therefore direct and unambiguous. The Opponent's rebuttal hinges on a semantic distinction between 'during a 12-month follow-up' and 'among patients 12 months after STEMI,' which is a straw man — the claim as stated does not specify a landmark analysis or post-12-month cohort, and the natural reading of '12 months after STEMI' is consistent with a 12-month follow-up period from the index event, exactly what Source 3 reports; the specific figures (26.4 mg/L cutoff, 12% vs 4% MACE) are directly corroborated, making the claim logically supported.
Expert 2 — The Context Analyst
The claim accurately reflects the exact statistical findings of a high-quality 2024 study (Source 3) regarding a 12% versus 4% MACE rate split by a median hs-CRP threshold of 26.4 mg/L over a 12-month follow-up. The opponent's objection relies on a pedantic semantic distinction between 'during a 12-month follow-up' and 'among patients 12 months after' the event, which does not distort the clinical reality or the truthfulness of the reported data.
Expert 3 — The Source Auditor
The most reliable and directly on-point evidence is Source 3 (JACC: Cardiovascular Imaging, 2024; hosted on PubMed Central), which explicitly reports that patients with hs-CRP above the median (>26.4 mg/L) had more major adverse cardiac events than those at/below the median (12% vs 4%) over a median follow-up of ~12 months; other high-authority sources (e.g., Sources 1, 2, 5, 6, 13, 20) support hs-CRP as prognostic but do not corroborate this specific 26.4 mg/L cutoff or the exact 12% vs 4% 12-month rates. Because the claim's precise numbers match Source 3 but its wording (“Among patients 12 months after STEMI”) overstates/ambiguously reframes what Source 3 actually reports (cumulative incidence during ~12-month follow-up from the index event in a selected CMR cohort), the trustworthy evidence makes the claim directionally correct but phrased in a potentially misleading way rather than strictly true as written.